Zionexa USA and PETNET Solutions, Inc., have announced on May 27, 2020 that the Food and Drug Administration (FDA) has approved Cerianna™ (fluoroestradiol F 18) injection for intravenous use. Cerianna (fluoroestradiol F 18) is a molecular imaging agent indicated for use in positron emission tomography (PET) imaging for the detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. Cerianna (fluoroestradiol F 18) is the first FDA-approved F-18 PET imaging agent specifically indicated for use in patients with recurrent or metastatic breast cancer.

Cerianna website is now live – for more information about Cerianna and see full prescribing information, please visit www.cerianna.com (only accessible for visitors located in the United-States).


Recent Posts